The Center for Biosimilars recaps the top 5 biosimilars articles for the week of March 12, 2018.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of March 12.
Number 5: The European Commission has issued its eighth report on drug patent settlements, in which it found that pay-for-delay settlements in Europe have stabilized at a low level.
Number 4: A recently published study finds that biosimilar infliximab is the most cost-effective biologic treatment for fistulizing Crohn disease.
Number 3: A study investigating drivers of high spending on healthcare in the United States found that brand-name drug prices play a key role.
Number 2: Results from the VOLTAIRE-RA study showed that switching from the reference adalimumab to Boehringer Ingelheim’s FDA-approved biosimilar did not impact efficacy, safety, or immunogenicity.
Number 1: A new report predicts that 2018 will mark the beginning of a new, large wave of biosimilars.
Finally, last week, our e-newsletter asked for your thoughts on whether patient assistance programs contribute to the problem of high drug costs. To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
BioRationality: MHRA's Procedure Enables Automatic Registration of Biosimilars Approved Elsewhere
March 18th 2024Sarfaraz K. Niazi, PhD, explains how the new international recognition procedure under the Medicines and Healthcare Products Regulatory Agency (MHRA) could expand biosimilar access within the United Kingdom, in his latest column.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.
Filgrastim Biosimilars in Europe: 15 Years of Real-World Evidence for Zarxio
March 13th 2024A review looking back at the last 15 years of experience with the first filgrastim biosimilar (Zarxio) provides a detailed overview on how filgrastim biosimilars came to be and the evidence behind why oncologists have come to accept them as standard practice.